SCHEDULE: Acorn Bioventures Discloses 6.4% Stake in Jasper Therapeutics

Acorn Bioventures and related entities, including Anders Hove, have disclosed beneficial ownership of 6.4% of Jasper Therapeutics, Inc.'s common stock.

Summary

• Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove have filed a Schedule 13G.
• The filing reports beneficial ownership of Jasper Therapeutics, Inc. common stock.
• Acorn Bioventures, L.P. and Acorn Capital Advisors GP, LLC each beneficially own 750,326 shares, representing 2.7% of the class.
• Acorn Bioventures 2, L.P. and Acorn Capital Advisors GP 2, LLC each beneficially own 1,036,166 shares, representing 3.7% of the class.
• Anders Hove, as Manager of the General Partners for both Acorn Bioventures funds, is deemed to beneficially own an aggregate of 1,786,492 shares, representing 6.4% of the class.
• The percentages are calculated based on 27,984,039 shares of Common Stock outstanding as of November 6, 2025, as reported in Jasper Therapeutics' Form 10-Q.
• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: This is a neutral filing, primarily a disclosure of beneficial ownership by an institutional investor. It does not contain information that would inherently sway sentiment positively or negatively regarding the company's operational or financial performance.

Positives

• A significant institutional investor, Acorn Bioventures, maintains a notable stake in Jasper Therapeutics, potentially signaling confidence in the company's long-term prospects.

Negatives

• The filing is a routine disclosure of beneficial ownership and does not contain information that would inherently be considered negative for the company's operations or financial health.

Risks

• The reporting persons explicitly state that their holdings are not for the purpose of changing or influencing control, which mitigates immediate governance risks from this specific filing, but the possibility of future nominations under Rule 240.14a-11 is noted.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Jasper Therapeutics, a company operating in the biotechnology sector. Such disclosures are common for publicly traded companies and reflect the investment activities of funds specializing in healthcare or life sciences.

Comparison to Industry Standards

• The beneficial ownership percentage of 6.4% by Anders Hove and related entities is a significant stake for an institutional investor in a biotechnology company, aligning with typical institutional investment strategies in the sector.
• The filing of a Schedule 13G under Rule 13d-1(b) indicates a passive investment intent, which is standard for many institutional holders who do not seek to control or actively influence the management of the issuer, unlike activist investors who would file a Schedule 13D.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Acorn Bioventures and Anders Hove provides transparency regarding the company's ownership structure. This can be viewed positively as it indicates institutional confidence, but also means a substantial block of shares is held by a single entity group.
• Management: The certification that the shares are not held for the purpose of changing or influencing control, other than potential nominations, suggests a passive investment approach, which generally reduces immediate pressure on current management.

Key Dates

Keywords

Jasper Therapeutics, Acorn Bioventures, Anders Hove, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Healthcare